Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. abt

ABT

AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ABT project word cloud

Explore the words cloud of the ABT project. It provides you a very rough idea of what is the project "ABT" about.

innovative    direct    7000    valuation    identification    positive    almost    community    cagr    biomedical    global    industry    infection    molecules    23    tecnology    disposal    accidents    abt    time    hire    waste    facilities    66    21    2022    saving    decreasing    amongst    investigation    solution    imply    axivirium    incorrect    strategy    nosocomial    degradation    100    reg    reducing    device    proper    14    environment    competitors    customer    feasibility    hazardous    virus    fluids    biological    economic    impacts    employees    estimate    annually    sterilize    reduce    survey    healthcare    validate    cross    axvirium    ip    million    natural    20    market    adantium    8    world    bioactive    ing    hiv    caused    16    day    completely    structures    accounted    rnases    validation    health    efficiency    eur    plus    hepatitis    2018    200    barriers    individuals    care    posing    occupational    billion    cut    improper    39    commercial    skilled    diseases    18    infectious    segments    risks    organisation    medical    worldwide    fluid    anticipated    tons    nearly   

Project "ABT" data sheet

The following table provides information about the project.

Coordinator		 ENPROJECT MEDICALI SRL 

Organization address
address: VIALE CARLO FAINA 30
city: MARSCIANO
postcode: 6055
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website https://www.enprojectmedicali.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENPROJECT MEDICALI SRL IT (MARSCIANO) coordinator 50˙000.00

Map

 Project objective

The aim of the project is to validate the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT) an innovative biomedical device, based on the Adantium® Plus and Axivirium BIOACTIVE® molecules, enable to cut biological risks, improve efficiency and reduce cost of health care biomedical fluids disposal. Medical waste is posing a growing problem worldwide resulting in nearly 7000 tons every day of infectious /hazardous medical waste and 10 billion euro annually in disposal cost across the European health care industry. According to the World Health Organisation (WHO), incorrect and improper management of healthcare biological fluids can have direct impacts on the community, individuals working in health care facilities, and the natural environment. It estimated that at world level accidents caused by not proper biological risks management accounted for 66,000 cases of infection with the hepatitis B virus, 16,000 cases of infection with hepatitis C virus and 200 to 5,000 cases of HIV infection amongst the personnel of health-care facilities. Compared to competitors ABT is the unique solution able to reach 100% degradation of RNases almost in real time and completely sterilize biological fluids. This imply saving operational cost up to 20%, decreasing occupational diseases by 39% and reducing cross- nosocomial infection by 14%. In 2018, the valuation of the global fluid management market was EUR 10 billion and is anticipated to reach EUR 18 billion by 2022, at a positive CAGR of 4.8% in the next three years. The estimated market potential for ABT is about 21 million euro and we estimate to hire 23 high skilled employees. The feasibility study comprises an investigation of market structures, segments and barriers, a customer survey and product validation, the identification of key commercial partners and the development of an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

AUTHEVOO (2019)

DNA-Authenticity & Traceability for Extra Virgin Olive Oil: Τrust the DNA, the label.

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More